{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:54Z","timestamp":1791950934773,"version":"4.3.4"},"reference-count":55,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Observational findings demonstrating improved survival for younger adults following pediatric, as opposed to adult, acute lymphoblastic leukemia (ALL) regimens have been translated into international, prospective multicenter clinical trials testing the pediatric regimen in young adult ALL. The results of these studies confirm the feasibility of delivering the pediatric regimen in the adult oncology setting and establish the superiority of this approach relative to historical adult cooperative group regimen results. Specific toxicities, including thrombosis, hepatotoxicity, and osteonecrosis, are more prevalent in adults receiving the pediatric regimen relative to young children. Persistent minimal residual disease (MRD) is a strong prognostic indicator in adults receiving the pediatric regimen; sensitive, high-quality MRD evaluation should be performed in all patients receiving these therapies. Incorporation of targeted agents, particularly in the frontline and MRD+ setting, will usher in the next era of the pediatric regimen in adult ALL.<\/jats:p>","DOI":"10.1182\/hematology.2019000009","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:09:46Z","timestamp":1575644986000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?"],"prefix":"10.1182","volume":"2019","author":[{"given":"Lori","family":"Muffly","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology & Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019120610090308100_B1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019120610090308100_B2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019120610090308100_B3","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019120610090308100_B4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"2019120610090308100_B5","article-title":"Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children\u2019s Oncology Group [published online ahead of print 28 February 2019]","author":"Steinherz","journal-title":"Leukemia"},{"issue":"14","key":"2019120610090308100_B6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2019120610090308100_B7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2009.262","article-title":"Long-term results of the Children\u2019s Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children\u2019s Oncology Group report","volume":"24","author":"Gaynon","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019120610090308100_B8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"M\u00f6ricke","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019120610090308100_B9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019120610090308100_B10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019120610090308100_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019120610090308100_B12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802 [published correction appears in Cancer. 2014;120(14):2222]","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2019120610090308100_B13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019120610090308100_B14","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-M\u00fcnster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"2019120610090308100_B15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019120610090308100_B16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019120610090308100_B17","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019120610090308100_B18","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019120610090308100_B19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009;27(15):2574]","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019120610090308100_B20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2019120610090308100_B21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2019120610090308100_B22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"2019120610090308100_B23","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25229","article-title":"Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: hyper-CVAD vs. pediatric-inspired regimens","volume":"93","author":"Siegel","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2019120610090308100_B24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"key":"2019120610090308100_B25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.06.010","article-title":"The Dana Farber consortium protocol (DFCP) vs. classic hyper-CVAD for treatment of acute lymphoblastic leukemia in patients &lt;50 Y. Single institution experience","volume":"60","author":"Alabdulwahab","year":"2017","journal-title":"Leuk Res"},{"issue":"5","key":"2019120610090308100_B26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ejh.12269","article-title":"High relapse rate of T cell acute lymphoblastic leukemia in adults treated with hyper-CVAD chemotherapy in Sweden","volume":"92","author":"Kozlowski","year":"2014","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019120610090308100_B27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019120610090308100_B28","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2019120610090308100_B29","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2018-99-116744","article-title":"Decrease of asparaginase induced thrombotic events with antithrombin III monitoring and repletion [abstract]","volume":"132","author":"Grose","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2019120610090308100_B30","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3109\/10428194.2016.1165815","article-title":"An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events","volume":"57","author":"Farrell","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019120610090308100_B31","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.clml.2018.02.014","article-title":"L-carnitine and vitamin B complex for the treatment of pegasparaginase-induced hyperbilirubinemia","volume":"18","author":"Rausch","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019120610090308100_B32","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"2019120610090308100_B33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2019120610090308100_B34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2019120610090308100_B35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2019120610090308100_B36","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2019120610090308100_B37","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019120610090308100_B38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2019120610090308100_B39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019120610090308100_B40","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2019120610090308100_B41","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"29","key":"2019120610090308100_B42","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019120610090308100_B43","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/pbc.25451","article-title":"Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"2019120610090308100_B44","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2014-01-552166","article-title":"6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"124","author":"Bhatia","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019120610090308100_B45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/leu.2009.303","article-title":"The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"key":"2019120610090308100_B46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/asheducation-2018.1.146","article-title":"Long-term complications in adolescent and young adult leukemia survivors","volume":"2018","author":"Baker","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2019120610090308100_B47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2019120610090308100_B48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/jayao.2018.0140","article-title":"Hematopoietic cell transplantation in young adult acute lymphoblastic leukemia: a United States population-level analysis","volume":"8","author":"Muffly","year":"2019","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"3","key":"2019120610090308100_B49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1055-9965.EPI-16-0722","article-title":"Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at specialized cancer centers on survival outcome","volume":"26","author":"Wolfson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2019120610090308100_B50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/hematology.2019000008","article-title":"Navigating the nexus of MRD and novel agents in ALL","volume":"2019","author":"Advani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2019120610090308100_B51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 15","key":"2019120610090308100_B52","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1200\/JCO.2018.36.15_suppl.10500","article-title":"COG AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy [abstract]","volume":"36","author":"Dunsmore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019120610090308100_B53","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019120610090308100_B54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2019120610090308100_B55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/17\/1546149\/hem2019000009c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/17\/1546149\/hem2019000009c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:10:03Z","timestamp":1575645003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/17\/422609\/Pediatricinspired-protocols-in-adult-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000009","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}